Abstract:Abstract Background Subjective cognitive decline (SCD) may provide an early indicator of evolving neurodegenerative disease. Dyadic SCD patterns, or understanding the self/patient’s in relation to an informant/loved one’s endorsement of SCD, may more accurately reflect underlying Alzheimer’s disease (AD) pathology in particular. We related dyadic discrepancies in SCD to markers of core AD pathology, including amyloid‐β 42 (Aβ 42 ) and phosphorylated tau (p‐tau). Method Vanderbilt Memory and Aging Project participants free of clinical dementia [n = 150, 72±7years, 37% mild cognitive impairment (MCI)] and their informants completed the Everyday Cognition questionnaire. Dyadic discrepancy (self‐reported score minus informant‐reported score) was calculated. Positive scores indicate self>informant SCD and negative scores indicate informant>self SCD. Participants also underwent fasting lumbar puncture to obtain cerebrospinal fluid (CSF) for quantification of Aβ 42 and p‐tau. Linear mixed‐effects regression models related dyadic score to individual CSF biomarkers adjusting for age, sex, self‐reported race/ethnicity, cognitive status, apolipoprotein E‐ ε4 status (positive, negative), and depression symptoms (Geriatric Depression Scale) with false discovery rate (FDR) corrections for multiple comparisons. Models were repeated with a diagnosis x biomarker interaction. Result SCD discrepancy in the negative direction (informant>self‐SCD) was associated with higher CSF p‐tau (β = ‐0.64, pFDRself‐SCD) had lower Aβ 42 levels (β = 5.592, pFDR = 0.02), indicating more cerebral amyloid deposition. The opposite pattern was observed in cognitively unimpaired participants, though findings did not survive FDR correction (β = 1.16, p = 0.03, pFDR = 0.24). Additionally, in MCI participants, negative SCD discrepancy was associated with higher p‐tau levels (β = ‐0.7223, pFDR = 0.02). All significant results survived outlier exclusion. See Figure for details. Conclusion Dyadic SCD discrepancy correlates with AD biomarkers differently in preclinical and prodromal states. In MCI, greater informant‐SCD related to more amyloid and p‐tau deposition, likely due to patient anosognosia and increasing functional changes noted by others. Conversely, in an earlier, preclinical stage before the onset of overt problems, more self‐SCD appears indicative of greater amyloid pathology. Results are consistent with the purported pathological cascade of AD and highlight the relevance of considering dyadic SCD to inform underlying disease.

Examining the Complicated Relationship Between Depressive Symptoms and Cognitive Impairment in Preclinical Alzheimer Disease

Exploring the Relationship Between Amyloid Burden and Depression in Pre-clinical Alzheimer's Disease

Neurometabolic Characteristics in the Anterior Cingulate Gyrus of Alzheimer’s Disease Patients with Depression: a 1H Magnetic Resonance Spectroscopy Study

Prevalence of Neuropsychiatric Symptoms Across the Declining Memory Continuum: an Observational Study in a Memory Clinic Setting

Interactions between mild depressive symptoms and amyloid pathology on the trajectory of neurodegeneration, cognitive decline, and risk of Alzheimer's disease

Depression related cerebral pathology and its relationship with cognitive functioning: A systematic review

Depressive symptoms and cognitive decline in older adults

Longitudinal Association of Depressive Symptoms with Cognition and Neuroimaging Biomarkers in Cognitively Unimpaired Older Adults, Mild Cognitive Impairment, and Alzheimer’s Disease

Depressive Symptoms Are Not Associated with Predementia Cerebrospinal Fluid Amyloid Pathology

Dyadic patterns of subjective cognitive decline relate to Alzheimer’s disease biomarkers differently in preclinical and prodromal clinical states

Depressive symptoms accelerate cognitive decline in amyloid-positive MCI patients

Longitudinal association of depressive symptoms with cognition and neuroimaging biomarkers in cognitively unimpaired older adults, mild cognitive impairment, and Alzheimer's disease

The Relationship Between Brain Aging and Preclinical Alzheimer′s Disease

Amyloid Pathologies Modulate the Associations of Minimal Depressive Symptoms With Cognitive Impairments in Older Adults Without Dementia

The relationship between depressive symptoms and cognitive function in Alzheimer's disease: The mediating effect of amygdala functional connectivity and radiomic features

Brain Functional Alterations and Association with Cognition in People with Preclinical Subjective Cognitive Decline and Objective Subtle Cognitive Difficulties.

P4‐137: THE CLINICAL CHARACTERISTICS AND RELATED FACTORS OF ALZHEIMER'S DISEASE WITH DEPRESSION

Altered Hippocampal Network Activity Links Memory Deficits and Depressive Symptoms in Amnestic Mild Cognitive Impairment

Cognitive Performance Deficits Are Associated with Clinically Significant Depression Symptoms in Older US Adults

Disentangling Sex-Dependent Effects of APOE on Diverse Trajectories of Cognitive Decline in Alzheimer's Disease

Unravelling the relationship between amyloid accumulation and brain network function in normal aging and very mild cognitive decline: a longitudinal analysis